Allele Partners

CAPITALIZING LEADERSHIP ACUMEN FOR LIFE SCIENCE INNOVATIONS

WE ADVISE, INVEST AND RAISE CAPITAL FOR PRIVATE AND PUBLIC

LIFE SCIENCE COMPANIES________________

Small Molecules | Biologics | Devices | New Technologies

Allele partners with executive leaders demonstrating exceptional results (ELDERs™) in the life sciences industry to provide strategic advisory, proprietary capital and non-proprietary capital.

Read More

TESTIMONIALS________________

"Allele Capital is a world-class group of seasoned professionals who have propelled my company into the public markets thereby allowing us to maximize our impact on patients and create value for our shareholders. I view Allele as an extension of our management team, focused on planning and executing our capital markets strategy. I have been deeply impressed with the time that the team dedicates to us, their deep understanding of the segment in which we operate, the outstanding strategic guidance and also the breath of their network (including investors, board talent, bankers, analysts, etc.). I have worked with many top scientific researchers, business leaders, and marquis investors over the past several decades in more than two dozen companies. Allele is unique in that they are best-in-class in each of these areas but are also fully aligned in creating value for all shareholders. In this business, integrity is paramount as we are dealing with patient lives and shareholder dollars. Each member of the Allele team is of the highest integrity - a precious and rare commodity. I simply cannot recommend them highly enough."

Dietrich Stephan, PhD, Founder, Chairman and CEO NeuBase Therapeutics, Inc. (Nasdaq: NBSE)


"In 2015 during our company's founding, we began working with Shawn to assist us in raising capital and defining the focus of our company. Shawn has supported our strategic initiatives over the years through advisory and investment to help drive our success. He has always been available to help us as we transitioned through various company growth stages."

Stephen Glover, Co-Founder, Director and Chief Executive Officer ZyVersa Therapeutics


“In 2008 during our company’s inception, we began working with Shawn to advise us on various aspects of our corporate planning and to assist us in raising capital. Over the years, Shawn has supported us in our company’s growth initiatives through investment, advice and capital markets support. We view Shawn as a value-added advisor and investor”.

Robert Finizio, Co-Founder and Chief Executive Officer TherapeuticsMD, Inc. (Nasdaq: TXMD)


"Menachem shared our vision and believed in our team pre Proof of Concept. He identified our risk mitigated scientific strategy of developing proprietary versions of already approved therapeutic proteins, extending their lifespan without additional toxicity or loss of desired biological activity. He invested his own capital and used his network to become a champion of our company."

Shai Novik, Former Chief Executive Officer Prolor Biotech, Inc. - Acquired by OPKO Health, Inc. (Nasdaq: OPK) in 2013


OUR APPROACH________________

Allele’s Principals comprehensive experience in private-to-public and public venture process for micro and small-cap life sciences companies has resulted in significant shareholder equity and valuations of over $1 billion.

 NEWS  ________________

ZyVersa Therapeutics featured in August 15th BioCentury “Biotechs Explore the Next Generation of Inflammasome Targets, with Caution”
August 19, 2019


See All News